-
公开(公告)号：US20220242910A1
公开(公告)日：2022-08-04
申请号：US17579463
申请日：2022-01-19
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Jae Young SEONG , Jong-Ik HWANG , Dong-Hoon KIM , Gi Hoon SON , Yoo-Na LEE , Seongsik YUN , Arfaxad REYES-ALCARAZ
IPC: C07K7/08 , A61P25/28 , A61P25/30 , A61P25/22 , A61P25/18 , A61P25/24 , A61P25/06 , A61K9/00 , A61K9/19
Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
-
公开(公告)号：US20240238445A1
公开(公告)日：2024-07-18
申请号：US18552290
申请日：2022-07-08
Applicant: NEURACLE SCIENCE CO., LTD. , KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION , KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS
Inventor： Jae Young SEONG , Youngjoo BYUN , Hoyun KWAK , Sitaek OH , Min-Hyeok LEE , Yongwoo JEONG , Nui HA , Eun-Ho CHO , Suhyun LEE , Sang-Myeong LEE , Yerim LEE , Eun Bee CHO , Jae Keun LEE , Han-Byul KIM , Soon-gu KWON
IPC: A61K48/00 , A61K31/055 , A61K31/085 , A61K31/136 , A61K31/137 , A61K38/08 , A61K38/10 , A61K38/17 , A61K45/06 , A61K47/64 , A61P25/02 , A61P25/28 , C12N5/0793
CPC classification number: A61K48/005 , A61K31/055 , A61K31/085 , A61K31/136 , A61K31/137 , A61K38/08 , A61K38/10 , A61K38/1709 , A61K45/06 , A61K47/64 , A61P25/02 , A61P25/28 , C12N5/0619
Abstract: The present disclosure provides mimic molecules that are capable of specifically targeting a FAM19A5 protein, and thereby, inhibiting, reducing, and/or dissociating the interaction between members of the LRRC4 protein family and the FAM19A5 protein. The present disclosure also provides methods for promoting neurite outgrowth, by administering a mimic molecule described herein.
-
公开(公告)号：US20230348584A1
公开(公告)日：2023-11-02
申请号：US18158259
申请日：2023-01-23
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol KIM , Eun Bee CHO , Dong Sik KIM , Jae-Keun LEE , Soon-gu KWON , Jae Young SEONG , Juwon SHIM , Tae Woo KIM , Shin-hyuk KANG
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
4.发明申请公开(公告)号：US20190300599A1
公开(公告)日：2019-10-03
申请号：US16348058
申请日：2017-11-07
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol KIM , Jae Young SEONG , Jong Ik HWANG , Eun Bee CHO , Junho CHUNG , Junyeong JIN , Tae Young YUNE , Jee Youn LEE
IPC: C07K16/18 , G01N33/563
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US20250067755A1
公开(公告)日：2025-02-27
申请号：US18776405
申请日：2024-07-18
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young SEONG , Byung Joo HAM , Min-Hyeok LEE , Nui HA
IPC: G01N33/68 , C07K16/24 , C12Q1/6883
Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.
-
Patent Agency Ranking
公开(公告)号：US20240166735A1
公开(公告)日：2024-05-23
申请号：US18350287
申请日：2023-07-11
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young SEONG , Jong Ik HWANG , Woong SUN , Eun Bee CHO , Won-Ki KIM
IPC: C07K16/24 , A61K38/17 , A61K48/00 , C07K14/47 , C07K16/18 , C12N15/113 , C12Q1/6886 , G01N33/577 , G01N33/68 , A61K39/00
CPC classification number: C07K16/24 , A61K38/1709 , A61K48/00 , C07K14/4701 , C07K14/4702 , C07K16/18 , C12N15/113 , C12Q1/6886 , G01N33/577 , G01N33/6896 , A61K2039/505 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C12N2310/11 , C12N2310/141 , C12Q2600/156 , G01N2333/47
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
-
公开(公告)号：US20200010509A1
公开(公告)日：2020-01-09
申请号：US16511976
申请日：2019-07-15
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Jae Young SEONG , Jong-Ik HWANG , Dong-Hoon KIM , Gi Hoon SON , Yoo-Na LEE , Seongsik YUN , Arfaxad REYES-ALCARAZ
IPC: C07K7/08 , A61K9/19 , A61K9/00 , A61P25/06 , A61P25/24 , A61P25/18 , A61P25/22 , A61P25/30 , A61P25/28
Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
-
公开(公告)号：US20220372122A1
公开(公告)日：2022-11-24
申请号：US17723149
申请日：2022-04-18
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol KIM , Jae Young SEONG , Jong Ik HWANG , Eun Bee CHO , Junho CHUNG , Junyeong JIN , Tae Young YUNE , Jee Youn LEE
IPC: C07K16/18 , G01N33/563 , C07K7/00
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US20200223914A1
公开(公告)日：2020-07-16
申请号：US16626625
申请日：2018-06-27
Inventor： Bongcheol KIM , Eun Bee CHO , Dong Sik KIM , Jae-Keun LEE , Soon-gu KWON , Jae Young SEONG , Juwon SHIM , Tae Woo KIM , Shin-hyuk KANG
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
公开(公告)号：US20240175880A1
公开(公告)日：2024-05-30
申请号：US18552293
申请日：2022-11-23
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Jae Young SEONG , Hoyun KWAK , Sitaek OH , Min-Hyeok LEE
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2800/28 , G01N2800/52
Abstract: The present disclosure relates to the use of LRRC4 family mimic molecules to determine the expression level of FAM19A5 protein in a subject. In some aspects, such mimic molecules can be used to identify and/or diagnose a subject suffering from or at risk of developing a disease or disorder associated with increased FAM19A5 protein expression. The present disclosure also provides methods of treating subjects identified and/or diagnosed using the methods provided herein.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.021 seconds)
